These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23599147)

  • 1. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.
    Wen YH; Brogi E; Hasanovic A; Ladanyi M; Soslow RA; Chitale D; Shia J; Moreira AL
    Mod Pathol; 2013 Sep; 26(9):1197-203. PubMed ID: 23599147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
    Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
    PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
    Vora HH; Patel NA; Thakore PM; Shukla SN
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):653-60. PubMed ID: 25789532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
    Xiong Y; Bai Y; Leong N; Laughlin TS; Rothberg PG; Xu H; Nong L; Zhao J; Dong Y; Li T
    Diagn Pathol; 2013 Feb; 8():27. PubMed ID: 23419122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor Gene Mutation Detection in Histology and Cytology Specimens of Primary Lung Adenocarcinoma: Immunohistochemistry Versus the Molecular Method.
    Abdul Hamid NS; Mat Zin AA
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1935-1942. PubMed ID: 34181354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunohistochemistry using epidermal growth factor receptor mutation-specific antibodies of delE746-A750 and L858R in lung adenocarcinomas].
    Fan XS; Liu B; Yu B; Shi SS; Wang X; Zhang J; Wang JD; Lu ZF; Ma HH; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):173-7. PubMed ID: 23769436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.
    Jie-Liu ; Li XY; Zhao YQ; Liu RQ; Zhang JB; Ma J; Chen LJ; Hu XF
    Pathol Res Pract; 2014 Mar; 210(3):176-81. PubMed ID: 24370340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma: evaluation of sensitivity, specificity and relationship to histologic subtypes].
    Lai YM; Feng Q; Sun Y; Wang P; Shi YF; Zhao M; Wu Q; Li XH
    Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):606-11. PubMed ID: 27646888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and β-catenin immunostaining for differentiation from metastatic colorectal carcinoma.
    Matsushima J; Yazawa T; Suzuki M; Takahashi Y; Ota S; Nakajima T; Yoshino I; Yokose T; Inoue T; Kawahara K; Nakatani Y
    Hum Pathol; 2017 Jun; 64():179-185. PubMed ID: 28438615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.
    Ping W; Xia C; Fu S; Cai Y; Deng Y; Sun W; Dong C; Fu X
    Tumour Biol; 2015 Feb; 36(2):693-700. PubMed ID: 25286755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
    Wang X; Wang G; Hao Y; Xu Y; Zhang L
    Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma.
    Ilie MI; Hofman V; Bonnetaud C; Havet K; Lespinet-Fabre V; Coëlle C; Gavric-Tanga V; Vénissac N; Mouroux J; Hofman P
    Virchows Arch; 2010 Oct; 457(4):483-95. PubMed ID: 20803030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
    Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
    J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.
    Simone G; Mangia A; Malfettone A; Rubini V; Siciliano M; Di Benedetto A; Terrenato I; Novelli F; Mottolese M
    J Exp Clin Cancer Res; 2010 Sep; 29(1):125. PubMed ID: 20843314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.